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Background: Data on birth outcome in women diagnosed with cancer before, during, or shortly 
after pregnancy are very sparse. The purpose of this review was to summarize the existing 
epidemiologic evidence of the adverse effect of breast cancer, cutaneous malignant melanoma, 
and Hodgkin’s disease on birth outcome.
Methods: The MEDLINE database was used to review the literature systematically. Studies 
that examined the following outcomes were included: preterm birth, low birth weight, low birth 
weight at term, stillbirths, congenital abnormalities, male proportion of newborns, and mean 
birth weight. Studies were grouped according to whether the woman had been diagnosed with 
the specific cancer before, during, or shortly after pregnancy.
Results: Few data exist on birth outcome in women with breast cancer, melanoma, or Hodgkin’s 
disease. The overall results from the limited number of studies, which included a comparison 
group for birth outcome, were reassuring. However, for women diagnosed with breast cancer 
before pregnancy, the only 2 studies that included comparison groups for birth outcome had 
conflicting results regarding the risk of preterm birth and congenital abnormalities.   Furthermore, 
a recent cohort study of birth outcome in women who were diagnosed with Hodgkin’s disease 
before pregnancy indicated a slightly increased risk of congenital abnormalities among the 
newborns.
Conclusion: Overall, the existing studies offer reassuring results concerning the risks of 
adverse birth outcome for women diagnosed with breast cancer, melanoma, or Hodgkin’s disease 
before, during or shortly after pregnancy. A limitation of most studies was the imprecise risk 
estimates caused by the small number of adverse birth outcomes and the lack of results stratified 
by treatment. Therefore, international collaboration is necessary in the future, to obtain more 
precise risk estimates for adverse birth outcomes, and to allow stratified analyses according to, 
for example, treatment.
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Introduction
In Western countries women often postpone childbearing for personal or professional 
reasons.1 The average age of Danish women at their first delivery has gradually increased 
from 23 years in the 1960s to 29 years in 2008.2 Because the incidence rates of most 
cancers increase with advancing age3 more women can be expected to be diagnosed 
with cancer before childbearing, during pregnancy, or shortly after giving birth.
In Denmark, the most common malignancy affecting women of childbearing age 
is breast cancer, and the second most common one is cutaneous malignant melanoma 
(excluding nonmelanoma skin cancer).3 Hodgkin’s disease, whose incidence peaks in 
early adulthood and thus also affects women of childbearing age, belongs to cancers Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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with a good prognosis.4 While in previous decades   pregnancy 
in patients with a history of cancer was discouraged,5 cur-
rently such pregnancies are treated with more optimism, 
partly owing to the improved prognosis for several cancers,6 
and partly because pregnancies subsequent to breast cancer, 
for example, do not seem to adversely affect maternal life 
expectancy.7–9 Because of a growing population of young 
  cancer survivors, however, concerns have been raised about 
the adverse effects of cancer and cancer therapy on the 
offspring of the treated individuals.10 Offspring include 
those conceived after completion of treatment, and fetuses 
exposed to cancer therapy in utero. Data on birth outcome 
in women diagnosed with cancer before, during, or shortly 
after pregnancy are very sparse. Thus the purpose of this 
review was to summarize the existing epidemiologic evidence 
of the adverse effect of breast cancer, cutaneous malignant 
melanoma, and Hodgkin’s disease on birth outcome.
Incidence of breast cancer, cutaneous 
malignant melanoma, and Hodgkin’s 
disease in women of childbearing age
Breast cancer
Breast cancer is the most common female cancer in 
  Denmark with more than 4000 women diagnosed every year 
(approximately 400 women are younger than 45 years of age 
at the time of diagnosis).3 The age-standardized   incidence rate 
of breast cancer has almost doubled over the last 4 decades, 
but this increase is mainly confined to women aged between 
45 and 75 years.11 The incidence of breast cancer in   pregnancy 
is unknown, but is estimated to range from 1 in 3000 to 1 in 
10,000 pregnancies.12
Cutaneous malignant melanoma
For decades, the incidence of cutaneous malignant melanoma 
has been rising in most white populations around the world.13 
In Denmark, the incidence of melanoma for women aged 15 
to 34 years increased, on average, by 4.3% annually from 
1970 to 1999,14 and in recent years, approximately 270 Danish 
women younger than 45 years have been   diagnosed annually 
with melanoma.3 It has been estimated that melanoma 
represents approximately 8% of malignancies diagnosed 
during pregnancy.15
Hodgkin’s disease
Hodgkin’s disease is characterized by a bimodal age   incidence 
curve, with the first peak in young adults and the second in 
old-age groups.16 While age standardized incidence of 
Hodgkin’s disease has been declining slightly over time, the 
true incidence in older age groups has in fact decreased 
substantially, whilst among young adults in industrialized 
countries increases have been documented.16 In 2000, 
29 women younger than 45 years of age were diagnosed with 
Hodgkin’s disease in Denmark.17 Hodgkin’s disease during 
pregnancy has a reported incidence ranging from 1 per 
100,000 to 1 per 6000 deliveries.18,19
Definition of birth outcomes
This review focuses on the prevalence of specific birth out-
comes for children of cancer patients. It does not examine 
the risk of spontaneous or induced abortions, or diseases 
diagnosed later in life. The birth outcomes examined are 
defined below:
Preterm birth
Preterm birth is defined as delivery before 37 completed 
weeks of gestation. The time of delivery depends both 
on the natural course of the pregnancy and on clinical 
  interventions, which may either shorten or prolong   gestation. 
Given this mixture of spontaneous events and effects of 
medical interventions, the outcome of preterm birth itself 
is heterogeneous.20
Low birth weight
Low birth weight (LBW) is defined as birth weight of less 
than 2500 g. Children in this group represent a mix of 
newborns whose growth is suboptimal, newborns delivered 
early, and newborns who are small for genetic reasons.20 As 
an alternative, some studies use “LBW at term” (defined 
as birth weight less than 2500 g in those born at least 37 weeks 
after conception), which suggests that the child remains 
small despite having had adequate time for growth.20 The 
presumption is that a child with LBW at term is likely to be 
growth retarded.
Stillbirth
In Denmark stillbirth is defined as antepartum or intrapartum 
fetal death after 22 completed weeks of pregnancy. Before 
2004 only fetal deaths after 28 completed weeks of pregnancy 
were considered stillbirths.
Congenital abnormalities
Congenital abnormalities occur in 3% to 5% of all live-
births.20 However, each individual type of congenital 
abnormality is rare, with the most common occurring in 
about 1/1000 live births.20 The etiologic events that gener-
ate structural abnormalities typically occur within the first Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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2 to 8 weeks post-conception, but the recognition of the 
abnormality may not occur until later in pregnancy (during 
ultrasound evaluation), at birth, in early childhood, or in 
adulthood, or the abnormality may never be recognized.
Male proportion of newborns
Approximately 51% of live-born children in Denmark are 
boys.
Methods
The epidemiologic evidence of the possible adverse effect 
of maternal breast cancer, melanoma, and Hodgkin’s disease 
on birth outcome was examined via a systematic literature 
review, including studies published before January 2010.
To review the literature, I searched the MEDLINE data-
base and used the MeSH (Medical Subject Heading) terms 
“breast neoplasms”, “melanoma”, and “Hodgkin disease” 
[MAJR] (Major Topic headings only), respectively, in com-
bination with “pregnancy” [MAJR], limiting the search to 
include only studies on human females, in English, and with 
an abstract. More studies were identified through communica-
tion with other researchers and by reviewing the reference 
lists of relevant articles. Studies were classified as case-series, 
if they reported birth outcome in a cohort of women with 
cancer without comparing it with the outcome of a compari-
son group. However, if the authors computed risk estimates 
for adverse birth outcome in comparison with the general 
population, the study was classified as a cohort study.
The studies listed in Tables 1, 2, and 3 were selected 
according to these criteria: studies of birth outcome in 
women who were diagnosed with breast cancer, melanoma, 
or Hodgkin’s disease at any time before pregnenancy (includ-
ing childhood), during pregnancy, or within 2 years after 
delivery were included. I selected only studies that examined 
preterm birth, LBW (or LBW at term), stillbirths, congenital 
abnormalities, male proportion of newborns, and/or mean 
birth weight. I excluded studies that reported overall risks 
of adverse birth outcome for survivors of different cancers 
combined. In addition, I excluded reviews, case-reports, 
case-series, and comments from the tables. However, given 
that the overall evidence on the topic is sparse, there are some 
references to case-series in the text.
Results
Below is a summary of the existing epidemiologic evidence of 
the adverse effect of maternal breast cancer, melanoma, and 
Hodgkin’s disease on birth outcome. The studies of birth out-
come in women with, respectively, breast cancer, melanoma, 
and Hodgkin’s disease (Tables 1, 2, and 3) were selected 
according to the inclusion criteria described under Methods. 
No case-control study fulfilled the inclusion criteria.
Birth outcome in women  
with breast cancer
Data on birth outcome in women diagnosed with breast 
  cancer before pregnancy are very sparse. Small case series 
have reported births of healthy children to women who 
became pregnant after being diagnosed with breast cancer.21,22 
The only 2 studies with a comparison group for birth outcome 
that have been published, however, had conflicting results 
on the risk of preterm birth and congenital abnormalities 
after breast cancer (Table 1).23,24 In a registry-based cohort 
study from Sweden, Dalberg et al examined 331 births 
from 1973 to 2002, to women who were diagnosed with 
breast cancer before pregnancy.24 Dalberg et al found that 
a large majority of these births were free of adverse events, 
and reported no increased risk of stillbirth or reduced birth 
weight for gestational age. However, the study also reported 
an increased risk of very preterm birth (,32 weeks) (odds 
ratio [OR] = 3.2; 95% confidence interval [95% CI]: 1.7–6.0) 
and LBW (,1500 g) (OR = 2.9; 95% CI: 1.4–5.8) and an 
increased risk of congenital abnormalities (OR = 1.7; 95% 
CI: 1.1–2.5) among children of breast cancer survivors, 
compared with the general population. The increased risk 
of congenital abnormalities was seen especially in the births 
occurring in 1988 to 2002 (OR = 2.1; 95% CI: 1.2–3.7), which 
the authors explained by an increased use of chemotherapy 
in younger patients. The study, however, had no data on 
the treatment of women with breast cancer. In contrast, a 
nationwide Danish cohort study of 216 newborns of women 
diagnosed with breast cancer before pregnancy found no 
increased risk with respect to preterm birth, LBW at term, 
stillbirth, and congenital abnormalities as well as mean birth 
weight, compared with the outcomes of 33,443 births from 
unaffected mothers, and with results unaltered by stratifica-
tion by a treatment variable.23 As suggested by Dalberg et al 
the different results in the Swedish and the Danish cohorts 
may be caused by different degrees of misclassification of 
the outcome variables between the registries or differences 
in the use of adjuvant radiotherapy or systemic treatments 
after breast cancer.
The Danish cohort study also observed an 8-fold 
increased risk of preterm delivery among 37 women diag-
nosed with breast cancer during pregnancy, which reflected 
a higher rate of elective early delivery, probably to allow an 
early start to cancer therapy. After adjustment for gestational Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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age, there was a 240 g reduction (95% CI: -404; -76) in 
mean birth weight for newborns of women diagnosed with 
breast cancer during pregnancy.   Furthermore, the study 
showed a tendency towards an increased risk of preterm 
birth for 442 women diagnosed with breast cancer within 
2 years after delivery.23 The study found no increased risk of 
stillbirth or congenital abnormalities in women diagnosed 
with breast cancer during pregnancy or within 2 years of 
delivery.
These findings corroborate the results of 2 earlier cohort 
studies of birth outcome in women with breast cancer 
  diagnosed during or shortly after pregnancy (Table 1).18,25 
In these studies, however, the authors did not distinguish 
between birth outcome in women diagnosed with breast 
cancer during pregnancy and women diagnosed shortly after 
pregnancy. Smith et al identified 423 cases of breast cancer 
diagnosed from 9 months preceding delivery until 12 months 
after delivery over a period of 6 years in   California.18 After 
adjusting the analyses for maternal age, the authors reported 
an OR of 2.2 (95% CI: 1.7–2.8) for preterm birth, and an 
OR of 2.0 (95% CI: 1.0–4.1) for very low birth weight. 
The study concluded that the data were consistent with an 
obstetric practice involving elective early delivery for cancer 
patients. Likewise, a historical cohort study of 118 women, 
who were pregnant within 9 months before or 3 months 
after their first treatment for breast cancer, reported a higher 
proportion of preterm births among offspring of women with 
breast cancer compared with controls, mainly because elec-
tive cesarean sections were done more often to allow earlier 
start to cancer therapy.25 In that study, only 2 stillbirths and 
no congenital abnormalities were observed. The authors 
also reported a lower mean birth weight after adjustment 
for gestational age.
Three case-series of 24, 28, and 29 pregnant breast cancer 
patients, respectively, have reported that   chemotherapeutic 
treatment in the second and third trimester caused no 
  congenital abnormalities or other complications, except for 
intrauterine growth retardation (IUGR) in 1 case.26–28
Only 1 study examined the sex ratio among newborns 
and found no substantial differences in proportions of boys 
born to breast cancer patients compared with cancer-free 
mothers.23 Thus, the findings did not corroborate a theory 
of psychological stress29 (caused by a cancer diagnosis) 
or potential mutagenic exposure (from chemotherapy or 
radiation)30 reducing the male proportion of newborns. These 
findings are in line with earlier studies that examined the sex 
ratio for newborns of childhood cancer survivors and found 
no significant alterations.31–33Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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In conclusion, the overall results regarding the birth 
outcome among women with breast cancer are reassuring. 
However, additional studies of birth outcome in women who 
were diagnosed with breast cancer before pregnancy are 
needed to resolve the discrepancy between the findings of 
the Danish23 and the Swedish24 study.
Birth outcome in women  
with cutaneous malignant melanoma
A nationwide cohort study from Denmark (Table 2) found 
no excess risk with respect to preterm birth, LBW at term, 
stillbirth, and congenital abnormalities among 620 newborns 
of women who were diagnosed with melanoma before 
pregnancy or 88 newborns of women who were diagnosed 
during pregnancy, compared with, respectively, 29,788 and 
4180 newborns of cancer free women.34 Furthermore, there 
was no important difference in mean birth weight or male 
proportion of newborns between women with melanoma and 
comparison women. However, the study reported a prevalence 
odds ratio (POR) of 4.6 (95% CI: 1.7–12.3) for stillbirth 
among 351 newborns of women, who were diagnosed with 
melanoma within 2 years after the time of delivery. This 
finding, which was unexpected, has not been shown by other 
studies, and may have been a chance finding.
Two other cohort studies have examined birth outcome 
in offspring of women diagnosed with melanoma during or 
shortly after pregnancy (Table 2).35,36 In a hospital-based 
cohort study of 18 deliveries by women diagnosed with mela-
noma during pregnancy over a period of 30 years, there were 
17 live births and 1 anencephalic stillbirth.36 The newborns 
of women with melanoma had a lower mean birth weight 
than newborns of women without cancer, but there was no 
difference in mean gestational age. The authors suggested 
that the differences in birth weight were due to IUGR sec-
ondary to the melanoma, its therapies, or its complications. 
In that study, however, mean birth weights were based on 
only 9 melanoma-exposed newborns and 9 newborns of 
age-matched comparison mothers.
In a population-based cohort study, O’Meara et al 
identified 149 women diagnosed with melanoma during 
pregnancy and 263 women diagnosed within 12 months 
after delivery over a period of 9 years in California.35 That 
study and the Danish study34 were in agreement with respect 
to the findings of no increased risk of preterm birth or low 
birth weight among newborns of mothers with melanoma. 
For women diagnosed during pregnancy, O’Meara and 
colleagues reported an OR of 0.9 (95% CI: 0.5–1.6) for 
preterm birth and an OR of 0.8 (95% CI: 0.3–1.8) for LBW, 
adjusted for age and race. They found no fetal deaths in 
the exposed group and no increased risk of adverse birth 
outcome in women diagnosed with melanoma in the first post 
partum year. The study did not examine the risk of congenital 
abnormalities among newborns.
The overall results from these studies show no substan-
tially increased risk of adverse birth outcome for women 
with melanoma, with the possible exception of an increased 
risk of stillbirth for newborns of women diagnosed within 
2 years of delivery.
Birth outcome in women  
with Hodgkin’s disease
More studies have examined birth outcome in women with 
previous Hodgkin’s disease. Janov et al did not find any sub-
stantial increased risk of LBW and no congenital abnormalities 
among newborns of 15 women with prepregnancy Hodgkin’s 
disease compared with the general population (Table 3).37 
Likewise, Swerdlow et al reported no increased risk of pre-
term birth, LBW, stillbirth, or congenital abnormalities among 
49 children of 16 women and 11 men who had previously been 
treated for Hodgkin’s disease compared with the general pop-
ulation (Table 3).38 Another study, which compared 52 births 
by 29 women previously treated for Hodgkin’s disease with 
births by the women’s siblings, found no overall increased 
risk of congenital abnormalities and stillbirths combined 
among children of Hodgkin’s   disease patients. The study 
also found no association of birth outcome with radiotherapy 
alone (supra- or infradiaphragmatic), whereas women treated 
with both chemotherapy and radiation were more likely to 
give birth to an abnormal child (P = 0.047) (Table 3). The 
3   studies, however, were all based on small study populations 
and did not control for potential confounders.
Recently, a large cohort study of female survivors of 
childhood cancer found that 19.2% of 337 women with 
childhood Hodgkin’s disease had a preterm birth compared 
with 12.6% among sibling controls (Table 3).40 Another study 
reported 11 stillbirths among 729 births of female survivors 
of childhood Hodgkin’s disease, corresponding to a relative 
risk of 1.6 (95% CI: 0.64–4.03) (Table 3).41 In contrast, 
a recent Danish cohort study of birth outcome in women 
with previous Hodgkin’s disease found no increased risk 
of preterm birth and only 1 stillbirth among 192 women, of 
whom more than 75% had been diagnosed with   Hodgkin’s 
disease in adulthood ($20 years of age at diagnosis) 
(Table 3).42 The results from the Danish study, however, 
indicated a slightly increased risk of congenital abnormali-
ties among newborns of women with previous Hodgkin’s Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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disease (POR = 1.7; 95% CI: 0.9–3.1). Furthermore, it was 
reported, that the POR for congenital abnormalities increased 
with calendar time of Hodgkin’s disease diagnosis (ie, for 
1991–2000 the POR was 3.1 (95% CI: 1.4–6.9) compared 
with POR = 1.0 (reference) for 1970–1980).42
The Danish study also reported increased risk estimates 
for congenital abnormalities among newborns of women 
who were diagnosed with Hodgkin’s disease during or 
shortly after pregnancy, but these estimates were based on 
few outcomes and were therefore imprecise. However, it 
is important to emphasize that teratogens increase the rate 
of specific, rather than all abnormalities, and the study was 
unable to evaluate those.
Two studies reported an increased risk of preterm 
birth for women diagnosed with Hodgkin’s disease during 
pregnancy, which reflected a higher rate of elective early 
delivery (Table 3).18,42 In contrast, a historical cohort study 
by Lishner et al which included 40 births by women who 
were pregnant between 9 months before and 3 months 
after their first treatment for Hodgkin’s disease, reported 
no increased risk of preterm birth or induced deliveries 
(Table 3).19 Furthermore, the study indicated no difference 
in mean birth weight compared with controls, while the pro-
portion of stillbirths was not statistically different from that 
of the general population. The study reported 1 child with a 
congenital abnormality born to the only patient treated with 
chemotherapy in the first trimester.
There was no evidence of any substantial decrease in the 
male proportion of newborns among women diagnosed with 
Hodgkin’s disease before pregnancy, indicating that earlier 
treatment for Hodgkin’s disease is not a risk factor for early 
male abortion.42
For newborns of women diagnosed with Hodgkin’s disease 
during pregnancy, there was an increase in the male propor-
tion, compared with newborns of comparison mothers, which 
was surprising and could have been a chance finding.42
In conclusion, the overall results are reassuring regard-
ing the risks of adverse birth outcome for women with 
Hodgkin’s disease, although the possibility of an increased 
risk of congenital abnormalities in newborns of women 
diagnosed with Hodgkin’s disease before pregnancy cannot 
be ruled out.
Discussion
Possible adverse effects of cancer  
and cancer therapy on birth outcome
When cancer is diagnosed in pregnancy, there is often 
a   conflict between optimal maternal therapy and fetal 
  well-being.5 The benefit of the diagnostic work-up, surgery, 
radiotherapy and chemotherapy must be weighed carefully 
against the risk to the fetus.12 Under these circumstances, 
preterm labor is often induced as soon as the fetus becomes 
viable, in order to allow amplification of therapy.12
The rationale for examining birth outcome in women 
diagnosed with cancer within a few years after delivery is 
that pregnancies starting before the diagnosis may be affected 
by the preclinical cancer. A Swedish study, which compared 
observed to expected rates of cancer during pregnancy and 
during the first year after delivery, suggested that diagnosis is 
often delayed to the postpartum period.43 A possible explana-
tion for this delay could be that unusual signs and symptoms 
may be ascribed to the pregnancy rather than the cancer.
For women who retain or regain fertility after cancer 
treatment, an issue of great importance is their ability to 
carry a pregnancy to term and give birth to a normal child. 
Chemotherapy and radiotherapy may affect future pregnan-
cies in cancer survivors by directly affecting the reproductive 
tract or by causing mutations in germ cells.30 It is therefore 
important to establish the magnitude of an increased risk (if 
any) of adverse birth outcomes such as preterm birth, LBW 
(or LBW at term), stillbirth, and congenital abnormalities.
Possible adverse effects of the cancer 
itself on birth outcome
Little is known about exact mechanisms whereby maternal 
cancer may pose risk to a developing fetus. In theory, several 
factors might influence the fetus if the mother has malignant 
disease:
•  It has been proposed that the cancer may alter metabolism 
and distribution of hormones and vitamins, some of which 
are determinants for certain congenital abnormalities.44
•  Cancer patients have an increased tendency to suffer from 
febrile illness,5 and maternal fever in early pregnancy 
has been associated with stillbirth45 and congenital 
abnormalities.45,46
•  Malnutrition is more frequent in the patients. Maternal 
undernutrition during pregnancy resulting in reduced 
transfer of nutrients to the fetus may cause fetal 
undernutrition and intrauterine growth retardation.47 
Impaired fetal growth is strongly associated with neonatal 
morbidity and mortality,48 and may also be associated 
with diseases later in life.49
•  Psychological stress related to severe life events (eg, a 
cancer diagnosis) around the time of conception may 
reduce the male proportion of newborns through differen-
tial conception or differential abortion of male   embryos.29 Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Likewise, some studies have reported   associations of 
stress in pregnancy with preterm delivery,50,51 and con-
genital abnormalities.52
Possible adverse effects of specific cancer 
therapy on birth outcome 
Surgery
Most surgical interventions can be safely undertaken with 
minimum risk during pregnancy, although there is almost 
always some element of maternal–fetal conflict.53
Radiation
Radiation is commonly used for cancer diagnosis and 
treatment. The fetus is sensitive to ionizing radiation, with 
the brain being the most sensitive organ.54 During the peri-
implantation and immediate post-implantation periods, 
radiation has an all or nothing effect, resulting in either 
embryonic death or further normal development. Later in 
pregnancy, radiation may cause congenital abnormalities, 
IUGR, mental retardation, or childhood cancer.54 As a 
result, the general recommendation is to postpone radio-
therapy until after delivery.12 At the same time, births of 
healthy children after radiotherapy of pregnant women for 
breast cancer and supradiaphragmatic Hodgkin’s disease 
have been reported (with appropriate shielding of the 
fetus).19,55–57
In nonpregnant women of childbearing age, ionizing 
radiation may damage ovarian function, cause premature 
ovarian failure, or trigger germ cell mutations, which can 
lead to congenital abnormalities in future offspring.30
Studies of women exposed to the atomic-bomb radiation 
and their subsequently conceived offspring have indicated a 
higher rate of spontaneous abortion, but showed no increase 
in the risk of major congenital abnormalities compared with 
the children of women from the general population.10 These 
results corroborate studies of childhood cancer survivors 
reporting no increased risk of congenital abnormalities 
or genetic diseases in the offspring of women exposed to 
  pre-gestational radiotherapy.58–61
It has also been postulated that maternal gonadal exposure 
to radiation would decrease the male proportion of new-
borns by inducing recessive sex-linked lethal mutations.62 
In   addition, women previously treated with high-dose 
abdominal radiotherapy have been found to have an increased 
risk of spontaneous abortions,41,63,64 preterm deliveries,40 and 
LBW infants58,59,63 during subsequent pregnancies.These 
effects are most likely due to radiation-induced damage to 
the women’s abdominopelvic structures.10,59
Traditional ways to protect the ovaries against the 
radiation damage are shielding of the ovaries and, in case of 
pelvic lymph node irradiation, repositioning of the ovaries 
out of the irradiation field (oopheropexy).65 Today, many 
young patients needing radiotherapy (or chemotherapy) are 
offered the option of cryopreservation of their ovarian tissue, 
while recent studies of ovarian tissue autotransplantation 
offer promising results.66
Chemotherapy
A potential teratogenic effect of chemotherapy   during 
pregnancy depends on the agent used, the timing of   exposure, 
the dose, and the characteristics affecting placental transfer.
Use of chemotherapy during the first trimester increases 
the risk of miscarriage and congenital abnormalities.26 
A review of 139 cases of first-trimester exposure to chemo-
therapy reported a total of 24 (17%) infants with congenital 
abnormalities after a single agent exposure, and a prevalence 
of 25% after combination-agent exposure.67
Chemotherapy during the second and third trimesters 
may increase the risk of preterm birth, IUGR, and stillbirth.12 
Furthermore, the central nervous system continues to develop 
after the first trimester, which makes it sensitive to insults 
during the entire pregnancy.12 While exposure to chemo-
therapy after the first trimester does not cause macroscopic 
anatomical defects, it may have long-term subanatomical 
consequences, for example, by interfering with the neuronal 
proliferation and migration.12 However, a study of late side 
effects among 84 children whose mothers received chemo-
therapy, during pregnancy, for hematological malignancies 
did not show impairments in learning behavior, or neuro-
logical abnormalities after a median follow-up of 18 years.68 
Given all the evidence, it is generally recommended that 
chemotherapy is delayed until after the first trimester.12
In nonpregnant women of childbearing age, chemotherapy 
can adversely affect fertility.69 Damage to the ovarian tissue 
depends on the agent used, the dose, and the age of the patient 
at treatment.70 Furthermore, chemotherapy is potentially muta-
genic10 with animal studies showing that it can cause mutations 
in oocytes and increase the risk of fetal abnormalities.65
Endocrine therapy
The use of anti-estrogenic therapy, such as tamoxifen, 
in   pregnant breast cancer patients has been discouraged 
because of teratogenic effects seen in animal models.12 Direct 
evidence for teratogenesis in humans is limited, with only 
isolated reports of rare forms of congenital abnormalities 
associated with tamoxifen use.71Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
18
Langagergaard
Conclusions and perspectives
This review summarizes the existing epidemiologic evidence 
of the adverse effect of maternal breast cancer, melanoma, 
and Hodgkin’s disease on birth outcome. On the whole, 
existing studies offer reassuring results concerning the risks 
of adverse birth outcome for women diagnosed with breast 
cancer, melanoma, or Hodgkin’s disease before, during or 
shortly after pregnancy. However, a limitation of most studies 
was the imprecise risk estimates caused by the small number 
of adverse birth outcomes and the lack of results stratified by 
treatment. Since even countrywide data may be sparse, an 
international collaboration is required in order to assemble 
data on a sufficient number of births by women with cancer 
in order to obtain more precise risk estimates for adverse 
birth outcomes. Moreover, a larger number of birth outcomes 
would allow stratified analyses according to, for example, 
different treatment regimens, stages, and how close in time 
the cancer diagnosis was to pregnancy. Information on these 
clinical details could be obtained from hospital medical 
records and clinical databases.
Very few studies document the long-term follow-up of 
children exposed to maternal cancer and cancer treatment in 
utero.68 Maternal cancer may affect not only birth outcome, 
but also long-term health, as a consequence of intra-uterine 
programming. Thus, large cohort studies with long term 
follow-up are needed to evaluate the entire spectrum of 
adverse effects of cancer or cancer treatment on offspring 
of the patients.
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